Ribavirin

Generic Name
Ribavirin
Brand Names
Ibavyr, Rebetol, Virazole
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
36791-04-5
Unique Ingredient Identifier
49717AWG6K
Background

Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...

Indication

Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...

Associated Conditions
Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
Associated Therapies
-
Clinical Trials
Related News

Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection

Not Applicable
Completed
Conditions
HIV Infections
Hepatitis C
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
24
Registration Number
NCT00015652
Locations
🇺🇸

Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

and more 5 locations

A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-28
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
20
Registration Number
NCT00000833
Locations
🇺🇸

Schneider Children's Hosp, New Hyde Park, New York, United States

🇺🇸

Children's Hosp of Boston, Boston, Massachusetts, United States

🇺🇸

Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States

and more 12 locations

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Phase 2
Completed
Conditions
HIV Infections
Hepatitis C
First Posted Date
2001-08-31
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
132
Registration Number
NCT00008463
Locations
🇺🇸

Ucsf Aids Crs, San Francisco, California, United States

🇺🇸

The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States

🇺🇸

Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States

and more 21 locations

A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2008-08-26
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
20
Registration Number
NCT00000699
Locations
🇺🇸

George Washington Univ Med Ctr, Washington, District of Columbia, United States

Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-11-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
42
Registration Number
NCT00000733
Locations
🇺🇸

Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States

🇺🇸

Tulane Univ School of Medicine, New Orleans, Louisiana, United States

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

First Posted Date
2001-06-28
Last Posted Date
2014-10-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
36
Registration Number
NCT00018031
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

Phase 4
Completed
Conditions
Chronic Hepatitis C
First Posted Date
1999-11-04
Last Posted Date
2017-07-02
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
50
Registration Number
NCT00001854
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Combination Drug Therapy for Patients With Hepatitis C

First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
120
Registration Number
NCT00001729
Locations
🇺🇸

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy